135.25 +0.58 (0.43%)
Pre-market: 6:45AM EDT
|Bid||135.00 x 800|
|Ask||135.84 x 800|
|Day's range||134.45 - 136.36|
|52-week range||121.00 - 148.99|
|Beta (3Y monthly)||0.76|
|PE ratio (TTM)||24.96|
|Forward dividend & yield||3.80 (2.83%)|
|1y target est||N/A|
Johnson & Johnson (JNJ) submits a BLA to the FDA, seeking approval for a subcutaneous formulation of its multiple myeloma drug.
AstraZeneca's (AZN) SGLT2 inhibitor, Farxiga, gets CRL from the FDA for a regulatory application seeking label expansion as a treatment for type I diabetes.
Lawyers for the state of Oklahoma on Monday compared Johnson & Johnson to a drug cartel leader as they sought to hold the drugmaker responsible for fuelling the U.S. opioid epidemic in the first trial to result from lawsuits over the crisis. Lawyers for the state, including Attorney General Mike Hunter, told a judge in Norman, Oklahoma that J&J's "greed" led the drugmaker to carry out a years-long marketing effort that caused "utter confusion" about the addictive painkillers' risks. Brad Beckworth, a lawyer for the state, said J&J knew opioids were harmful, yet minimized the risk of addiction in their marketing, resulting in a surge in overdose deaths as doctors overprescribed the drugs and they flooded the state.
With most blue-chip companies' earnings scheduled over the coming weeks and investors' sentiment being mixed, investors should closely monitor the movement of the Dow ETF.
Johnson & Johnson (JNJ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
According to Bloomberg, Johnson & Johnson (JNJ) plans to initiate a trial to evaluate its mosaic-based HIV-1 vaccine in the US and Europe this year.
The U.S. Justice Department is reportedly pursuing a criminal investigation as to whether J&J (JNJ) lied about the possible cancer risk associated with its talcum powder.
Second-quarter earnings are usually pretty sleepy, with forecasts for the back-to-school and holiday periods tucked away for later review amid summer vacation schedules. You may want to pay attention this year, though.
Johnson & Johnson is scheduled to report second-quarter earnings before the market open on Tuesday. Most recent news about J&J (JNJ) has been about its legal problems, but some analysts still think the future is bright for the baby-powder maker, thanks to a highly diversified slate of products spanning consumer health, pharmaceuticals and medical devices. “We see JNJ’s diversified portfolio... as a potential strength,” analysts at Goldman Sachs wrote in a note to clients in May. That diversification means the company “will be less impacted by potential drug pricing headlines [and] policy proposals ahead of the 2020 presidential election, as was the case in 2015,” they wrote.
Lawyers for the state of Oklahoma on Monday compared Johnson & Johnson to a drug cartel leader as they sought to hold the drugmaker responsible for fueling the U.S. opioid epidemic in the first trial to result from lawsuits over the crisis. Lawyers for the state, including Attorney General Mike Hunter, told a judge in Norman, Oklahoma that J&J's "greed" led the drugmaker to carry out a years-long marketing effort that caused "utter confusion" about the addictive painkillers' risks. Brad Beckworth, a lawyer for the state, said J&J knew opioids were harmful, yet minimized the risk of addiction in their marketing, resulting in a surge in overdose deaths as doctors overprescribed the drugs and they flooded the state.
The S&P 500 closed above the 3,000 level for the first time, with the industrial, consumer discretionary and materials sectors each posting gains of at least 1%. Illumina Inc shares tumbled 16.1%, the most among S&P 500 companies, after the gene sequencing company's preliminary second-quarter revenue came in below analyst estimates.
(Bloomberg) -- The U.S. Justice Department is pursuing a criminal investigation into whether Johnson & Johnson lied to the public about the possible cancer risks of its talcum powder, people with knowledge of the matter said.The criminal probe, which hasn’t been reported previously, coincides with a regulatory investigation and civil claims by thousands of cancer patients that J&J’s Baby Powder talc was responsible for their illness. Now, a grand jury in Washington is examining documents related to what company officials knew about any carcinogens in their products, the people said.Baby Powder accounts for only a tiny fraction of J&J’s annual revenue, but it’s been a core brand for the company for more than a century. Questions about the product’s safety have led to more than 14,000 lawsuits from consumers asserting that the company’s talc products caused their ovarian cancer or mesothelioma, a rare form of the disease linked to asbestos exposure.J&J disclosed in February that it had received subpoenas, but little was known then about the investigation behind them, including whether the matter was civil or criminal. The filing didn’t mention a grand jury.The company said in a statement Friday that there had been no new developments. “We have been fully cooperating with the previously disclosed DOJ investigation and will continue to do so,” said J&J spokeswoman Kim Montagnino. “Johnson’s Baby Powder does not contain asbestos or cause cancer, as supported by decades of independent clinical evidence.”The Justice Department didn’t respond to requests for comment.Shares of J&J declined by 4.2% to close at $134.30, after falling as much as 5.6%.Internal MemosJ&J, the world’s largest maker of health care products, has said safety tests of its Baby Powder over many decades have shown no presence of asbestos. But some of the lawsuits have turned up internal memos as far back as the 1960s and ’70s that contain warnings from company scientists that asbestos detected in J&J’s talc was a “severe health hazard” that could pose a legal risk for the company.Justice Department prosecutors, FBI agents and Securities and Exchange Commission regulators are almost surely looking at whether J&J officials’ public denials that their talc-based products ever contained asbestos were truthful, legal experts said. SEC spokeswoman Judy Burns declined to comment.Nearly a dozen juries have concluded J&J knew that some of their Baby Powder and former Shower-to-Shower products had at least trace amounts of asbestos and failed to disclose that to consumers. Over the past three years, jurors have awarded a total of more than $5 billion to people who blame the powders for their cancers.The company has said it has set aside money for legal costs related to talc claims but hasn’t said how much. Bloomberg Intelligence estimates that civil settlements could cost J&J as much as $15 billion overall. J&J says it has no liability because the products are safe.Shares of J&J plunged as much as 17% in December -- erasing billions in value -- after news reports about memos appearing to show that J&J executives knew the products were contaminated with asbestos as early as the 1970s.Document RequestsThe February document requests from the Justice Department, the SEC and the top Democrat on the Senate Committee on Health, Education, Labor and Pensions sought information about the company’s knowledge of asbestos in its talc-based products. J&J said it would be “cooperating with these government inquiries and will be producing documents in response.”The grand jury was impaneled after the Justice Department’s fraud unit started an investigation. Investigators are probably looking for more internal communications that might conflict with the company’s public statements, said Henry Klingeman, a former federal prosecutor now in private practice in New Jersey.“Since J&J is a public company, they are probably looking at whether their statements amounted to fraudulent statements to consumers and regulators,” Klingeman said in an interview. “I’d also think they’d be looking at whether they violated securities-fraud laws.”The grand jury inquiry is likely to influence any talks between J&J and plaintiffs over resolving their claims out of court, said Peter Henning, a law professor at Wayne State University in Detroit.“This will make it more difficult for Johnson & Johnson to settle the civil cases as long as there is a continuing criminal investigation, which may require employees to testify before a federal grand jury,” Henning said. “Civil plaintiffs may not want to settle until they know better whether criminal charges will be filed, which they can use to aid their cases.”Investor SuitsIn addition to the consumers’ suits, some J&J investors have accused the company of defrauding them, arguing in lawsuits that J&J failed to disclose that its powder was tainted and that the company’s shares were artificially inflated as a result.Jacob Frenkel, a former SEC trial lawyer now in private practice in Washington, said there’s no timeline for grand-jury investigations and no certainty it will result in charges. “This could be a high-profile government investigation that goes nowhere,” he said. “Regardless of the outcome, the timetable for such investigations can measure in years, not months,” he added.Baby powder is mostly talc, a mineral used to keep skin dry and as an astringent to prevent diaper rash. It’s also used in consumer products such as makeup, paint and dietary supplements. But geological formations that contain talc also yield asbestos, a mineral once used in products such as building insulation.Scientists have found strong links between asbestos and mesothelioma, while plaintiffs’ lawyers claim that studies have also shown a link between talc and ovarian cancer. In court filings, J&J has disputed both contentions.Indemnity AgreementJ&J sold the rights to its Shower-to-Shower talcum powder to Valeant Pharmaceuticals International Inc. in 2012. Valeant, which changed its name to Bausch Health Cos last year, has an indemnity agreement with J&J covering asbestos suits tied to the powder.Juries in states such as Missouri, California and New Jersey have ruled for some of the plaintiffs since suits started going to trial in 2016. However, some of those verdicts have been thrown out by judges and others are on appeal. Some other cases have resulted in hung juries or outright wins for J&J.Most of the ovarian cancer cases, along with investors’ suits, have been consolidated before a federal judge in New Jersey for pretrial information exchanges and test trials. The first trials of those cases haven’t yet been set.Read More:J&J’s $4.69 Billion Talc Loss Hands Investors a What-Next MomentJ&J Must Pay $72 Million Over Talc Tied to Woman’s CancerImerys Talc Units File Bankruptcy as Cancer-Suit Risk SoarsJ&J Plan to Move Talc Cases Stumbles as Women Too Ill for Delays(Updates with closing share price.)\--With assistance from Michelle Fay Cortez, Matt Robinson and Tom Schoenberg.To contact the reporter on this story: Jef Feeley in Wilmington, Delaware at firstname.lastname@example.orgTo contact the editors responsible for this story: Winnie O'Kelley at email@example.com, ;Heather Smith at firstname.lastname@example.org, David S. Joachim, David GlovinFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
U.S. stocks hit record highs on Friday as high expectations for an interest-rate cut from the Federal Reserve continued to propel shares while investors awaited next week's kickoff of the corporate earnings season. The S&P 500 traded above the 3,000 level for a third straight session, with industrial and consumer discretionary posting gains of 1% or more. "All this week has been the Federal Reserve's influence," said Mark Kepner, equity trader at Themis Trading in Chatham, New Jersey.
The Bloomberg report said the grand jury was looking into documents related to what company officials knew about any carcinogens in their products. J&J disclosed in its annual report in February that it had received subpoenas from the Justice Department and Securities and Exchange Commission related to the ongoing baby powder litigation but did not give more details.
Shares of Johnson & Johnson fell 4.3% in Friday afternoon trade after Bloomberg reported that the U.S. Justice Department is pursuing a criminal investigation into whether the company lied about the possible cancer risks of its talcum powder. A grand jury in Washington is examining documents related to what J&J officials knew about carcinogens in their products, according to the Bloomberg report. The health-products company is already facing thousands of lawsuits over the safety of its talc-containing baby powder and its alleged role in fueling the opioid crisis. In February, J&J disclosed it had received subpoenas from the Justice Department at the Securities and Exchange Commission seeking documents related to the safety of its baby powder and other talc-containing products. Shares of J&J have gained 3.9% so far this year, while the S&P 500 has gained 20%. The Dow Jones Industrial Average has gained 16.1%.
J&J has denied allegations that its talc causes cancer. It said numerous studies and tests by regulators worldwide have shown that its talc is safe and asbestos-free.